Search Job Title Only
News By Subject
News by Disease
News By Date
Get Our FREE
) to Liquidate Under Chapter 11
6/2/2009 7:09:50 AM
Reuters -- Northfield Laboratories, whose human red blood cell substitute was denied U.S. regulatory approval, filed for bankruptcy protection on Monday to liquidate its assets.
(NFLD) Terminates All of its Operational and Staff Employees and Shuts Down
TorreyPines Therapeutics, Inc.
(TPTX) Board Approves Liquidation
(NFLD) Receives Complete Response Letter for PolyHeme BLA; Data Inadequate for Final Approval Action
(EDEN) Announces Shareholders' Approval of Plan of Dissolution and Liquidation
(NFLD) Implements Measures to Preserve Cash; Eliminates 13 Positions
Targeted Genetics Corporation
(TGEN), Mainstay of Gene Therapy, Faces Likely Shutdown
New Study Demonstrates Use of
(NFLD)'s PolyHeme(R) Mitigates Tumor Progression in Pancreatic Cancer Model
(GENR) Shutting Down; Company Announces Approval of Plan of Liquidation and Dissolution by Board of Directors
(NFLD) Announces Closing of Financing
Prospect Therapeutics, Inc.
Assigns All Its Assets for the Benefit of Its Creditors
comments powered by Disqus.
comments powered by
Biotech/Pharma - Chapter 7, 11